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Introduction: Gout results from an innate immune response to monosodium urate (MSU) crystals deposited in
joints. Increased very low-density lipoprotein (VLDL) has been associated with gout. The apolipoprotein B (apo B),
which is present on VLDL, regulates neutrophil response to MSU crystals and has been positively associated with
gout. Furthermore, the gene (A1CF) encoding the complementation factor for the APOB mRNA-editing enzyme is
associated with urate levels. However, the relationship of apo B and VLDL with gout and hyperuricaemia (HU) is still
unclear. Therefore, we tested the association of VLDL and apo B with HU and with gout compared to HU.
Methods: New Zealand European (n = 90) and Māori and Pacific Island (Polynesian) (n = 90) male gout case and
control sample sets were divided into normouricaemia (NU), asymptomatic HU and gout groups. Size exclusion
chromatography and enzyme-linked immunosorbant assay was used to measure VLDL and apo B. Multivariate
logistic regression was used to assess the risk of gout and HU per unit change in VLDL and apo B.
Results: Increased levels of VLDL triglycerides (Tg) were observed in the gout sample set compared to NU and HU
in Europeans (P = 1.8 × 10-6 and 1 × 10-3, respectively), but only compared to NU in Polynesians (P = 0.023). This
increase was driven by increased number of VLDL particles in the European participants and by the Tg-enrichment
of existing VLDL particles in the Polynesian participants. Each mmol/L increase in VLDL Tg was significantly associated
with gout in the presence of HU in Europeans, with a similar trend in Polynesians (OR = 7.61, P = 0.011 and 2.84,
P = 0.069, respectively). Each μmol/L increase in total apo B trended towards decreased risk of HU (OR = 0.47; P = 0.062)
and, conversely, with increased risk of gout compared to HU (OR = 5.60; P = 0.004).
Conclusions: Increased VLDL Tg is associated with the risk of gout compared to HU. A genetic approach should be
taken to investigate the possibility for causality of VLDL in gout. Apolipoprotein B may have pleiotropic effects in
determining HU and gout.Introduction
Gout is caused by activation of the innate immune system
in response to monosodium urate (MSU) crystals that are
deposited in joints when serum urate levels are elevated.
The genetic and environmental causal factors in determin-
ing hyperuricaemia (HU) are becoming better understood
[1,2]. However, causal mechanisms in determining gout in
the presence of HU are poorly understood. Along with
chylomicrons, very low-density lipoproteins (VLDL) are
the lipoproteins that primarily transport triglycerides (Tg)* Correspondence: tony.merriman@otago.ac.nz
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stated.with 86% and 55% of their core lipids constituting Tg,
respectively. Gout has been associated with increased
levels of VLDL Tg in a non-obese and non-drinking male
Japanese sample set [3] and type IV hyperlipoproteinaemia
(characterized by increased VLDL-Tg) is prevalent in
Japanese male gout patients (39%) [3]. The increased
VLDL Tg levels in gout could be caused, at least in part,
by reduced lipoprotein lipase activity [4]. Apolipoprotein
B (apo B), amongst other lipoproteins, coats MSU crystals
exposed to plasma and, when attached to MSU crystals as
part of an entire lipoprotein particle, can suppress the
stimulation of neutrophils [5]. Based on their previous
observation of elevated VLDL components and increased
ratio of apolipoprotein CIII (involved in VLDL clearance)l Ltd. This is an Open Access article distributed under the terms of the Creative
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Cardona et al. [6] demonstrated association of genetic var-
iants at the APOCIII locus with gout. Also, increased
VLDL Tg is associated with reduced urinary uric acid ex-
cretion [3,7]. Elevated serum apo B levels have also been
associated with primary gout [8]. Interestingly, there is as-
sociation between urate levels and risk of gout of the gene
(A1CF), which encodes the complementation factor for
the APOBEC enzyme that edits apo B mRNA [9,10].
Collectively the observations outlined above implicate
VLDL Tg and/or apo B in gout. However, the relation-
ship between VLDL-Tg, apo B and HU and gout is un-
clear. We hypothesized that if increased VLDL Tg plays
a role in regulation of the innate immune response to
MSU crystals in gout then this would be consistent with
association of VLDL Tg with gout compared to HU. We
also tested for association of circulating levels of apo B
with HU and gout compared to HU.
Methods
Participants
The 180 New Zealand (NZ) male participants consisted
of gout cases, defined by the American Rheumatology
Association preliminary classification criteria [11], and
controls, who self-reported their lack of gouty arthritis
and were at least 17 years of age. Gout cases were re-
cruited from the Auckland and Canterbury regions of
NZ. Participants without gout self-reported no diagnosis
of gout, and were convenience sampled from the Auck-
land and Otago regions of NZ. Control participants were
stratified into a normouricaemia (NU) group with serum
urate level of <0.41 mmol/L and a HU group with serum
urate level ≥0.41 mmol/L. All variables except for bio-
chemical measurements, body mass index (BMI) and
medications (obtained from medical records) were self-
reported. Ancestry was self-reported and participants
were divided into NZ Europeans and NZ Polynesians
(Māori and Pacific Island). Demographic, anthropo-
morphic and clinical data are reported in Table 1. The
New Zealand Multi-region Ethics Committee (MEC/
105/10/130) approved the study and all participants gave
written informed consent.
Biochemical measurements
Fast protein liquid chromatography (FPLC) was used to
fractionate lipoproteins from frozen non-fasting serum
samples. Tg and cholesterol assays were done on the FPLC
fractions to identify lipoprotein-containing fractions. Dilu-
tions of Precipath L (Roche, Mannheim, Germany) were
used to make a standard curve and all samples were tested
in triplicate. A total of 100 μL of each fraction was incu-
bated with 100 μL of Tg glycerol-3-phosphate oxidase-
phenol and aminophenazone (GPO-PAP) reagent (Roche/
Hitachi) or cholesterol oxidase (CHOD)-PAP reagent(Roche) for 15 to 20 minutes at 37°C in a 96-well plate
(Nunc™, Thermo Fisher Scientific, Waltham, MA, USA).
Non-fasting serum samples were studied because partici-
pants were convenience sampled from health care and
community settings.
An enzyme-linked immunosorbant assay (ELISA) was
used to measure apo B in serum and FPLC fractions as
previously described [12]. Cfas Lipid (Roche) with a
known apo B concentration of 2,185 nmol/L was used as
an internal control. The primary antibody used for apo
B measurement was a polyclonal antibody (Roche) and
the secondary antibody was an anti-sheep immuno-
globulin G (IgG) conjugated to horseradish peroxidase.
Total apo B values obtained from ELISA were adjusted
for the percentage lipid recovery from the FPLC. This
was done for each individual sample by multiplying the
total apo B value by the percentage recovery of plasma
lipids from the FPLC. Serum urate was measured by the
uricase oxidation method [13] and serum creatinine was
measured using the creatinine Jaffé compensated method
[14], the end point determined by a Roche Cobas™ 8000
analyser. The estimated glomerular filtration rate (eGFR)
was calculated using the Modification of Diet in Renal
Disease formula: eGFR (mL/min/1.73 m2) = 175 × ((SCr ×
0.0113)-1.154 × (Age-0.203).
Statistical analyses
Due to the skewed distribution of lipid-related pheno-
types, all lipid, lipoprotein and apolipoprotein values
were expressed as median and interquartile range (25th
to 75th percentile) and pairwise comparisons were done
using the Wilcoxon-Mann-Whitney test or Student t test
or chi-square test via the Intercooled STATA™ software
version 8.0 (StataCorp, College Station, TX, USA).
Multivariate-adjusted linear and logistic regression ana-
lyses were used to assess the association of VLDL and
other lipid variables with phenotype. A threshold of P
<0.05 was used to indicate statistical significance.
Results
Traces of Tg concentrations in FPLC fractionated lipo-
proteins (Figure 1) indicate differences in Tg content in
VLDL fractions between the gout and non-gout groups
in both Europeans and Polynesians. An increasing trend
in serum, total FPLC Tg and VLDL Tg from NU to HU
to gout was observed in both Europeans and Polynesians
(Table 2). VLDL Tg was significantly higher in gout than
NU and HU in Europeans (Table 2; P = 1.84 × 10-6 and
0.001, respectively) whereas the difference was signifi-
cant between NU and gout in Polynesians (Table 2;
P = 0.023). FPLC is a standard methodology used to sep-
arate lipoproteins by size [15]. The area under the curve
of the resulting lipoprotein peaks as identified by choles-
terol or triglyceride assay can be utilised to establish
Table 1 Characteristics of the sample sets
Polynesians P values
NU HU Gout NU vs. HU NU vs. Gout HU vs. Gout
Number 30 30 30 30 30 30
Age (year) 46.07 ± 12.18 45.83 ± 12.32 42.43 ± 9.95 0.94 0.21 0.24
Waist circumference (cm) 105.72 ± 11.03 111.31 ± 15.32 110.00 ± 11.20 0.12 0.15 0.71
BMI (kg/cm2) 32.97 ± 5.60 34.68 ± 6.06 34.52 ± 5.31 0.27 0.28 0.92
eGFR (mL/min/1.73 m2) 83.03 ± 16.14 72.30 ± 12.35 74.77 ± 15.36 0.0054 0.047 0.50
Hypertension (%) 17.24 16.67 26.67 0.95 0.38 0.35
Type 2 diabetes (%) 13.33 6.67 6.9 0.39 0.41 0.97
Statin use (%) 13.33 13.33 30.00 0.96 0.20 0.22
Fibrate use (%) _ _ 3.33 _ _ _
Tophi (%) _ _ 53.33 _ _ _
Allopurinol use (%) _ _ 68.97 _ _ _
Probenecid usage (%) _ _ 7.41 _ _ _
Fruit consumption (pieces per day) 2.62 ± 1.37 1.88 ± 1.46 1.23 ± 0.96 0.051 <0.00001 0.049
Sugary drink consumption (drinks per day) 2.41 ± 2.40 2.06 ± 1.91 2.78 ± 2.07 0.54 0.53 0.17
Alcohol consumption (drinks/week) 2.40 ± 6.02 4.23 ± 7.95 8.87 ± 13.53 0.32 0.020 0.11
Serum urate (mmol/L)1 0.346 ± 0.040 0.474 ± 0.063 0.469 ± 0.107 <0.00001 <0.00001 0.84
Europeans P values
NU HU Gout NU vs. HU NU vs. Gout HU vs. Gout
Number 30 30 30
Age (year) 57.67 ± 12.01 63.17 ± 13.61 53.60 ± 9.11 0.10 0.14 0.0022
Waist circumference (cm) 92.25 ± 15.08 99.38 ± 13.53 107.79 ± 9.92 0.090 <0.00001 0.0096
BMI (kg/cm2) 25.73 ± 6.53 28.85 ± 6.88 31.27 ± 4.18 0.12 0.0001 0.11
eGFR (mL/min/1.73 m2) 80.18 ± 12.49 65.91 ± 16.25 68.86 ± 17.47 0.0004 0.0059 0.50
Hypertension (%) 23.33 36.67 46.67 0.26 0.058 0.43
Type 2 diabetes (%) 3.45 6.9 3.33 0.55 0.98 0.53
Statin use (%) 20.00 23.33 16.67 0.75 0.74 0.52
Fibrate use (%) _ _ 3.33 _ _ _
Tophi (%) _ _ 13.79 _ _ _
Allopurinol use (%) _ _ 75.86 _ _ _
Probenecid usage (%) _ _ 3.7 _ _ _
Fruit consumption (pieces per day) 1.68 ± 1.09 2.27 ± 1.62 2.00 ± 1.39 0.11 0.33 0.50
Sugary drink consumption (drinks per day) 0.77 ± 1.27 1.42 ± 1.77 0.69 ± 1.04 0.11 0.79 0.060
Alcohol consumption (drinks/week) 5.40 ± 6.13 8.68 ± 14.72 6.53 ± 6.06 0.26 0.47 0.46
Serum urate (mmol/L) 0.321 ± 0.046 0.459 ± 0.041 0.403 ± 0.094 <0.00001 0.0001 0.0042
1In the European gout cases, 17 were HU and 13 NU at the time of recruitment. In the Polynesian cases, the corresponding numbers were 22 and 8, respectively.
NU: normouricaemia; HU: hyperuricaemia; BMI: body mass index; eGRF: estimated glomerular filtration rate.
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VLDL, low-density lipoprotein (LDL) and high-density
lipoprotein (HDL). Therefore lipid ratios rather than ab-
solute lipid values were used for further analyses. Sig-
nificant differences were found in the VLDL Tg to total
Tg ratio between European gout cases and HU and NU
in the three pairwise comparisons (Table 2; P = 0.0041to 1.23 × 10-06), with the ratio increasing from NU to HU
to gout. However, in the Polynesian groups, this ratio was
not significantly different between NU and HU controls
(P = 0.44) but was significantly increased in gout com-
pared to NU and HU (P = 0.0071 and 0.0011 respectively).
The VLDL apo B concentration was significantly higher
in HU and gout cases in Europeans compared to NU
Figure 1 Average triglyceride lipoprotein traces of gout cases and controls. Lipoproteins in plasma samples were separated by fast protein
liquid chromatography and each fraction was assayed for triglyceride concentration.
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compared to HU (P = 0.041). In the Polynesian group the
corresponding value for VLDL apo B concentration was
not significantly different between gout and the other sub-
groups, although it was higher in gout. There was a signifi-
cant increase in the VLDL apo B to total apo B ratio in
HU and gout compared to NU in Europeans and between
NU and HU in Polynesians (Table 2). There was no sig-
nificant difference in the VLDL Tg to VLDL apo B ratio
between European subgroups; conversely, in Polynesians,
this ratio was higher in gout compared to HU and NU
(Table 2; P = 0.0011 and 0.042, respectively). Collectively
these results suggested an increased number of VLDL par-
ticles in HU particularly in Europeans, with an increase inTg loading of these particles evidenced in gout in Polynes-
ian participants.
We tested the risk of gout compared to NU and HU for
three Tg phenotypes (Table 3; total serum Tg; total FPLC
Tg, VLDL Tg). In the presence of HU each mmol/L in-
crease in VLDL Tg associated with a 7.61-fold increase
in risk in Europeans (P = 0.011) and a trend towards
increased risk in Polynesians (odds ratio (OR) = 2.84;
P = 0.069), with significantly increased risk in the com-
bined ancestral groups (OR = 3.56; P = 0.002). These re-
sults were robust to exclusion of gout cases taking
fenofibrates or statins (Table 4). A significant effect was
seen for total FPLC Tg in Europeans comparing gout to
HU (OR = 5.19 per unit mmol/L increase, P = 0.014) but








P NU vs. HU P NU vs. Gout P HU vs. Gout
Number 30 30 30
Total serum cholesterol 5.71 [4.33-6.47] 5.73 [5.03-6.54] 5.99 [5.25-6.41] 0.48 0.47 0.86
Total FPLC cholesterol 4.75 [3.52-5.47] 4.16 [3.72-4.81] 4.00 [3.18-4.43] 0.25 0.074 0.41
LDL cholesterol 2.83 [2.20-3.22] 2.45 [2.14-3.09] 2.45 [1.99-2.97] 0.42 0.11 0.40
HDL cholesterol 1.13 [0.84-1.35] 0.96 [0.79-1.00] 0.77 [0.70-1.06] 0.030 0.0052 0.17
Total serum Tg 1.87 [1.15-3.04] 2.32 [1.83-3.29] 2.49 [1.46-4.36] 0.058 0.060 0.93
Total FPLC Tg 1.41 [0.97-2.16] 1.55 [1.23-1.80] 1.71 [1.09-2.85] 0.34 0.17 0.46
VLDL Tg 0.57 [0.37-1.18] 0.80 [0.61-1.06] 1.01 [0.60-2.11] 0.24 0.023 0.10
VLDL Tg:Total Tg 0.45 [0.32-0.61] 0.51 [0.43-0.60] 0.65 [0.53-0.75] 0.44 0.0071 0.0011
Total apo B (μmol/L) 1.09 [0.93-1.85] 0.94 [0.79-1.13] 1.10 [0.92-1.26] 0.026 0.59 0.020
VLDL apo B (μmol/L) 0.044 [0.028-0.079] 0.072 [0.045-0.101] 0.061 [0.028-0.132] 0.048 0.32 0.92
VLDL apo B:Total apo B 0.040 [0.025-0.077] 0.072 [0.050-0.11] 0.051 [0.022-0.121] 0.001 0.19 0.40
VLDL Tg:VLDL apo B 12.49 [7.95-20.14] 11.74 [8.23-15.26] 19.44 [13.61-25.83] 0.74 0.042 0.0011
Europeans
Number 30 30 30
Total serum cholesterol 5.56 [4.75-6.09] 5.60 [4.93-6.39] 5.11 [4.27-6.59] 0.77 0.37 0.36
Total FPLC cholesterol 4.18 [3.73-4.86] 4.01 [3.19-4.70] 4.19 [3.28-5.10] 0.21 0.70 0.50
LDL cholesterol 2.51 [2.06-2.97] 2.45 [1.86-2.83] 2.37 [1.83-3.59 0.46 0.68 0.75
HDL cholesterol 1.27 [1.21-1.57] 1.01 [0.79-1.21] 1.00 [0.89-1.10] 2.14E-05 0.0001 0.79
Total serum Tg 1.58 [1.05-2.00] 1.92 [1.50-2.80] 2.45 [1.70-2.90] 0.019 0.0008 0.21
Total FPLC Tg 1.11 [0.64-1.35] 1.15 [0.90-1.41] 1.57 [1.23-2.25] 0.17 0.0001 0.0021
VLDL Tg 0.36 [0.16-0.47] 0.47 [0.35-0.65] 0.84 [0.59-1.30] 0.008 1.84E-06 0.0010
VLDL Tg:Total Tg 0.32 [0.24-0.41] 0.43 [0.35-0.50] 0.68 [0.49-0.60] 0.0041 1.23E-06 0.0004
Total apo B (μmol/L) 1.31 [1.09-1.65] 1.06 [0.72-1.42] 1.36 [1.03-1.76] 0.036 0.88 0.053
VLDL apo B (μmol/L) 0.038 [0.021-0.072] 0.064 [0.035-0.103] 0.090 [0.062-0.125] 0.018 4.53E-05 0.041
VLDL apo B:Total apo B 0.032 [0.019-0.054] 0.063 [0.043-0.090] 0.069 [0.051-0.092] 0.0001 8.59E-06 0.37
VLDL Tg:VLDL apo B 8.33 [4.76-13.61] 8.62 [5.74-12.56] 10.45 [7.41-13.72] 0.92 0.16 0.16
All P values are calculated using the Wilcoxon-Mann-Whitney test. NU: normouricaemia; HU: hyperuricaemia; FPLC: fast protein liquid chromatography;
LDL: low-density lipoprotein; HDL: high-density lipoprotein; Tg: triglyceride; VLDL: very low-density lipoprotein; apo B: apolipoprotein B.
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nificant risk in gout associated with total serum Tg.
We next investigated apo B. It was notable that total
apo B was significantly lower in HU than in NU in both
ancestral groups (PEuropean = 0.036, PPolynesian = 0.026)
(Table 2). Given also the association in Europeans with
serum urate of the A1CF gene [9], which encodes a com-
plementation factor for the apolipoprotein B mRNA-
editing enzyme catalytic polypeptide 1 [16], we tested
the hypothesis that apo B is associated with HU by com-
paring total serum apo B levels between NU and com-
bined HU/gout groups (Table 5). Each unit increase
(μmol/L) in total circulating apo B was significantly
associated with reduced risk of HU in Polynesians
(OR = 0.20 [0.04 to 0.96], P = 0.044) but not in Europeans(OR = 0.46 [0.15 to 1.46], P = 0.19) with trending evidence
for a protective role in HU in the combined sample sets
(OR = 0.47 [0.21 to 1.04], P = 0.062). In contrast, each
100 nmol/L increase in VLDL apo B was not associated
with an increased risk of HU in Europeans (OR = 4.04
[0.82 to 19.83], P = 0.086) or Polynesians (OR = 1.81 [0.51
to 6.47], P = 0.36) although there was evidence for in-
creased risk of HU in the combined sample sets (OR =
2.50 [1.00 to 6.26], P = 0.050). There was, however, by lin-
ear regression analysis no association of apo B with urate
levels in the combined NU and HU groups (Table 5). We
also tested for a role of total circulating apo B in gout
compared to HU (Table 3), observing positive association
with gout (OR = 5.60 [1.73 to 18.18], P = 0.004 per μmol/L
unit change) although there was no evidence for association
Table 3 Analysis of association of gout risk with lipid and apo B-associated traits in study sample sets











Europeans 2.34 [1.22-4.49] 0.011 1.37 [0.70-2.65] 0.36 1.21 [0.73-1.99] 0.46 1.31 [0.72-2.40] 0.38
Polynesians 1.41 [1.00-1.98] 0.049 1.00 [0.51-1.98] 0.99 1.17 [0.85-1.62] 0.34 1.14 [0.75-1.75] 0.54
Combined 1.59 [1.17-2.17] 0.003 1.19 [0.80-1.75] 0.39 1.18 [0.90-1.54] 0.24 1.20 [0.88-1.65] 0.25
Total FPLC Tg (mmol/L)
Europeans 4.17 [1.51-11.51] 0.006 1.97 [0.75-5.15] 0.17 4.37 [1.49-12.81] 0.007 5.19 [1.39-19.33] 0.014
Polynesians 1.29 [0.80-2.10] 0.30 0.65 [0.28-1.50] 0.31 1.51 [0.82-2.78] 0.19 1.52 [0.68-3.41] 0.31
Combined 1.74 [1.14-2.64] 0.01 1.17 [0.69-1.96] 0.56 2.05 [1.23-3.42] 0.006 2.14 [1.17-3.90] 0.014
VLDL Tg (mmol/L)
Europeans 11.29 [2.40-53.00] 0.002 3.24 [0.87-12.07] 0.080 6.52 [1.70-24.99] 0.006 7.61 [1.60-36.26] 0.011
Polynesians 1.92 [1.01-3.67] 0.048 0.98 [0.34-2.81] 0.97 2.46 [1.11-5.44] 0.026 2.84 [0.92-8.76] 0.069
Combined 2.78 [1.55-4.99] 0.001 1.81 [0.87-3.75] 0.11 3.19 [1.62-6.24] 0.001 3.56 [1.60-7.92] 0.002
Total apoB (μmol/L)
Europeans 0.97 [0.36-2.63] 0.95 0.83 [0.18-3.76] 0.81 2.71 [0.94-7.76] 0.064 3.32 [0.87-12.61] 0.078
Polynesians 0.47 [0.18-1.23] 0.12 0.27 [0.04-1.73] 0.17 13.38 [1.48-120.76] 0.021 33.55 [1.16-972.93] 0.041
Combined 0.65 [0.34-1.26] 0.20 0.78 [0.32-1.93] 0.59 3.60 [1.41-9.17] 0.007 5.60 [1.73-18.18] 0.004
VLDL apo B (0.1 μmol/L)
Europeans 17.80 [2.99-106.02] 0.002 10.05 [1.16-87.35] 0.036 1.69 [0.74-3.86] 0.21 1.67 [0.62-4.51] 0.31
Polynesians 2.24 [0.89-5.60] 0.086 1.97 [0.48-8.12] 0.35 1.51 [0.61-3.73] 0.38 2.42 [0.70-8.36] 0.16
Combined 4.23 [1.87-9.59] 0.001 2.68 [1.03-6.95] 0.043 1.60 [0.87-2.93] 0.13 1.57 [0.80-3.09] 0.19
VLDL Tg:VLDL apo B
Europeans 1.06 [0.97-1.16] 0.20 1.02 [0.90-1.16] 0.78 1.06 [0.97-1.17] 0.20 1.02 [0.91-1.15] 0.68
Polynesians 1.05 [0.99-1.10] 0.086 1.03 [0.99-1.07] 0.19 1.08 [1.01-1.15] 0.024 1.08 [0.99-1.18] 0.061
Combined 1.04 [1.00-1.09] 0.051 1.03 [0.99-1.06] 0.15 1.06 [1.01-1.12] 0.016 1.06 [1.00-1.12] 0.045
Adjusted for age, BMI, type 2 diabetes, SSB intake (drinks/day), alcohol intake (drinks/week), eGFR, hypertension and prescription of lipid-lowering medication. The
Polynesian data are also adjusted by number of self-reported Polynesian grandparents. The combined analysis was additionally adjusted by ancestral group. NU:
normouricaemia; HU: hyperuricaemia; OR: odds ratio; CI: confidence interval; Tg: triglyceride; FPLC: fast protein liquid chromatography; VLDL: very low-density
lipoprotein; apo B: apolipoprotein B; BMI, body mass index; SSB: sugar-sweetened beverage; eGRF: estimated glomerular filtration rate.
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100 nmol/L unit change). Thus apo B negatively corre-
lated with HU, but positively correlated with gout in the
presence of HU.
Given the organised chronic inflammatory nature of
the tophus, with inflammatory factors that may promote
resolution of gout attacks [17] and thus create a different
inflammatory situation in acute tophaceous gout, we re-
peated the Table 3 analysis, but with tophaceous cases ex-
cluded (Table 4). Despite the exclusion of 53% of the
Polynesian and 14% of the European cases, the signifi-
cance of the total apo B and VLDL Tg: VLDL Apo B ratio
analyses in the previous HU compared to gout analysis
(Table 3) were strengthened (OR = 11.58, P = 0.001 com-
pared with OR = 5.60, P = 0.004 and OR = 1.07, P = 0.029
compared to OR = 1.06, P = 0.005 respectively).Discussion
We observed increased levels of VLDL Tg in gout com-
pared to asymptomatic HU. This increase was suspected
to be driven by overproduction of VLDL particles in HU
particularly in Europeans (as evidenced by a significantly
higher VLDL apo B to total apo B ratio in HU and gout;
Table 2) and additionally by the Tg-enrichment of exist-
ing VLDL particles (a significantly higher VLDL Tg to
VLDL apo B ratio in gout; Table 2) in the Polynesian
participants only. The association of each mmol/L in-
crease in VLDL Tg with risk of gout in the presence of
HU was restricted to Europeans (OR = 7.61, P = 0.011),
although there was a trend towards increased risk in
Polynesian participants (OR = 2.84, P = 0.069). We also
associated reduced total apo B with HU and increased
total apo B with gout compared to HU. Given this is a
Table 4 Analysis for association of gout risk with lipid and apo B-associated traits in non-tophaceous gout (left) and
gout excluding participants taking fenofibrate and statins (right)
HU vs non-tophaceous gout HU vs lipid-lowering excluded gout
Adjusted OR [95% CI] P Adjusted OR [95% CI] P
Total Tg (mmol/L)
Europeans 1.11 [0.55-2.26] 0.77 1.30 [0.367-2.51] 0.44
Polynesians 0.95 [0.50-1.80] 0.88 1.16 [0.68-1.96] 0.59
Combined 1.04 [0.72-1.50] 0.82 1.24 [0.86-1.78] 0.25
Total FPLC Tg (mmol/L)
Europeans 3.64 [0.96-13.82] 0.068 7.41 [1.42-38.56] 0.017
Polynesians 1.05 [0.29-3.77] 0.94 1.58 [0.62-4.05] 0.34
Combined 1.78 [0.91-3.48] 0.091 2.37 [1.17-4.83] 0.017
VLDL Tg (mmol/L)
Europeans 5.10 [0.97-26.81] 0.054 26.15 [2.48-276.04] 0.007
Polynesians 1.72 [0.37-7.96] 0.49 3.18 [0.84-12.05] 0.089
Combined 2.78 [1.13-6.79] 0.025 4.77 [1.76-12.96] 0.002
Total apo B (μmol/L)
Europeans 4.32 [0.86-21.69] 0.075 3.17 [0.71-14.09] 0.13
Polynesians 158.22 [1.95-1286.5] 0.024 7.23 [0.28-189.08] 0.24
Combined 11.58 [2.62-51.15] 0.001 4.32 [1.17-15.93] 0.028
VLDL apo B (0.1 μmol/L)
Europeans 1.99 [0.67-5.91] 0.22 1.85 [0.52-6.57] 0.34
Polynesians 0.39 [0.04-3.82] 0.42 1.80 [0.50-6.49] 0.37
Combined 1.32 [0.63-2.77] 0.46 1.64 [0.74-3.63] 0.23
VLDL Tg:VLDL apo B
Europeans 1.06 [0.93-1.21] 0.39 1.05 [0.92-1.20] 0.43
Polynesians 1.48 [1.02-2.15] 0.041 1.11 [1.00-1.24] 0.060
Combined 1.07 [1.01-1.15] 0.029 1.07 [1.00-1.14] 0.042
Adjusted for age, BMI, type 2 diabetes, SSB intake (drinks/day), alcohol intake (drinks/week), eGFR, hypertension and prescription of lipid-lowering medication for
the non-tophaceous analysis. The Polynesian data are also adjusted by number of self-reported Polynesian grandparents. The combined analysis was additionally
adjusted by ancestral group. HU: hyperuricaemia; OR: odds ratio; CI: confidence interval; Tg: triglyceride; FPLC: fast protein liquid chromatography; VLDL: very
low-density lipoprotein; apo B: apolipoprotein B; BMI, body mass index; SSB: sugar-sweetened beverage; eGRF: estimated glomerular filtration rate.
Table 5 Association analysis of apo B with hyperuricaemia (left) and serum urate (right)










Total apo B (μmol/L)
Europeans 0.58 [0.24-1.39] 0.22 0.46 [0.15-1.46] 0.19 -0.026 [-0.071-0.019] 0.26 -0.014 [-0.048-0.020] 0.41
Polynesians 0.27 [0.10-0.75] 0.012 0.20 [0.04-0.96] 0.044 -0.038 [-0.071–0.004] 0.031 -0.017 [-0.057-0.023] 0.40
Combined 0.41 [0.22-0.77] 0.005 0.47 [0.21-1.04] 0.062 -0.034 [-0.061–0.007] 0.013 -0.020 [-0.045-0.005] 0.12
VLDL apo B (0.1 μmol/L)
Europeans 8.13 [2.04-32.42] 0.003 4.04 [0.82-19.83] 0.086 0.046 [0.011-0.081] 0.011 0.001 [-0.002-0.004] 0.48
Polynesians 2.32 [0.89-6.05] 0.084 1.81 [0.51-6.47] 0.36 0.045 [-0.007-0.098] 0.089 -0.002 [-0.004-0.0004] 0.099
Combined 3.80 [1.74-8.33] 0.001 2.50 [1.00-6.26] 0.050 0.046 [0.017-0.075] 0.002 -0.001 [-0.003-0.0005] 0.18
Adjusted for age, BMI, type 2 diabetes, SSB intake (drinks/day), alcohol intake (drinks/week), eGFR, hypertension and prescription of lipid-lowering medication. The
Polynesian data are also adjusted by number of self-reported Polynesian grandparents. The combined analysis was additionally adjusted by ancestral group. NU:
normouricaemia; HU: hyperuricaemia; OR: odds ratio; CI: confidence interval; apo B: apolipoprotein B; VLDL: very low-density lipoprotein; BMI, body mass index;
SSB: sugar-sweetened beverage; eGRF: estimated glomerular filtration rate.
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ascribe causality to VLDL Tg and/or apo B in HU and in
gout compared to HU. However the data, when considered
with the previous literature, support further investigation of
the role of VLDLTg and/or apo B in HU and gout.
Apo B has been linked with downregulation of the in-
nate immune system and the resolution phase of acute
gout. When coating MSU crystals apo B suppresses neu-
trophil activation [5] (which is needed for endocytosis and
lysis of these crystals in gout [18]). This is consistent with
the clinical observation that apo B coats MSU crystals
only when inflammation subsides in gout [19]. Apo B pos-
sesses domains enriched in positively charged amino acids,
which have high affinity for binding to polyanionic mole-
cules such as MSU crystals [20]. Our data, however, that
associate increased levels of apo B with gout compared to
HU are not necessarily inconsistent with the previous ex-
perimental evidence. It is possible that increased circulat-
ing apo B correlate with reduced synovial apo B in
intercritical gout (all our participants were intercritical),
which would reduce the suppression of innate immunity
and increase the chance of acute gout. This hypothesis
could be tested by measuring apo B and VLDL apo B in
synovial fluid in NU, HU and gout. The maintenance of
the association of apo B with gout compared to HU when
tophaceous cases were excluded suggests heterogeneity
and that future studies investigating a possible role for
apo B in gout should stratify into tophaceous vs non-
tophaceous gout. Recently a male gout patient with mito-
chondriopathy in Kearns-Sayre syndrome (KSS) was
described [21]. This person had large MSU crystals that
were less immunogenic and that exhibited little synergy
with toll-like receptor 2 agonists, a response that was
hypothesised to be due to different crystal conformational
or chemicophysical properties. It would be interesting to
evaluate the lipoprotein profile of MSU crystals from the
KSS patient compared to non-syndromic gout patients.
Reduced total apo B was associated with HU whereas
increased total apo B was associated with gout compared
to HU. These observations suggest pleiotropic effects
of apo B in gout. Previously, serum urate control in
Europeans has been associated with genetic variation in
the A1CF gene [9], which encodes a complementation
factor for the apo B mRNA-editing enzyme catalytic
polypeptide 1 (APOBEC). This enzyme is part of a com-
plex that edits a translational stop codon within the apo
B mRNA, causing synthesis of apo B-48 (present on chy-
lomicrons) instead of the full-length apo B-100. In
humans, this editing takes place in the intestine whereas
apo B-100 (present on VLDL and LDL) is exclusively
produced by the liver [22]. While it has not been con-
firmed if A1CF is the causal gene at this locus, the max-
imally associated genetic variants at this locus all map
within A1CF [9] suggesting that this gene does controlurate levels. The genetic data are consistent with our as-
sociation of reduced total apo B levels with HU and lead
to the prediction that the urate-increasing A1CF allele
would functionally associate with reduced apo B. Col-
lectively these data raise the possibility that reduced apo
B is a risk factor for HU, yet increased VLDL Tg (with a
single apo B molecule per VLDL particle) could be in-
volved in gout in the presence of HU.
The fibric acid derivative fenofibrate is used in hyper-
triglyceridaemia to reduce VLDL, LDL and total triglyc-
erides. It activates peroxisome proliferator-activated
receptor alpha, which in turns activates lipoprotein lip-
ase to reduce circulating Tg-rich particles [23]. In pri-
mary hypertriglyceridaemia fenofibrate reduces serum
urate by increasing renal uric acid excretion via inhib-
ition of urate transporter 1 [24,25] and reduces Tg levels
without changing serum apo B levels [26]. Interestingly,
the established serum urate-increasing response to an
acute fructose load (ref [27] and refs therein) is negated
by fenofibrate [26], suggesting a link with carbohydrate
metabolism. Fenofibrate is not used as a primary man-
agement tool in gout, although its use is associated with
maintenance of normouricaemia after withdrawal of
frontline urate-lowering therapy in gout [28] and small
trials show efficacy as an adjunct treatment for gout
[29-31]. Our data, demonstrating a possible role for
VLDL in gout compared to HU are consistent with pre-
vious evidence [26] supporting the use of fenofibrate as
an adjunct treatment in gout with hypertriglyceridaemia.
One possible limitation of our study relates to the non-
fasting status of the participants. This would have intro-
duced additional variability into the Tg but not the apo B
data - in a study of healthy subjects at four and eight
hours postprandially, total apo B did not differ whereas
total Tg levels increased when compared to fasting [32]. It
is important to point out, however, non-fasting Tg and
other lipids are better predictors of cardiovascular disease
[33], supporting the use of non-fasting measures in study-
ing metabolic risk.
Consideration of genetic data does support the hy-
pothesis that aspects of Tg metabolism play a causal role
in gout. For example, there are loci associated with con-
trol of serum urate levels that contain genes that are also
associated with serum Tg levels (GCKR, MLXIPL, A1CF)
[9] and gout [9,10]. A Mendelian randomization study,
examining the relationship between the genetically at-
tributable fractions of urate and triglyceride, provides
evidence for a causal role of triglycerides in urate control
but not the reverse [34]. These genetic data and the ob-
servational data presented herein support further testing
of the hypothesis that apo B and VLDLTg play a causal
role in gout. For example, in large sample sets genetic
variants associated with apo B and VLDL Tg could be
tested for association with gout compared to HU controls.
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We report association of reduced total apo B with HU,
but increased apo B and VLDL Tg with gout compared
to HU. These data support the hypothesis that VLDL
metabolism plays a role in gout, with apo B having pleio-
tropic effects.
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